Drugs used in the treatment of oral mucosal diseases

The oral mucosa and the surrounding tissues are the entrance to the body, where oral mucosa-specific lesions can be seen, and where symptoms or signs of many systemic diseases can be observed. The etiology of the lesions occurring in the oral mucosa may be trauma, infection, immunological causes or idiopathic. Drug application onto the mucosa covering the oral cavity has long been a field of pharmacology. Lesions that occur as a symptom of systemic diseases are usually seen as ulcerations. The purpose of the treatment is to apply symptomatic treatments that mainly improve the patient’s comfort while solving the underlying problem. These are achieved primarily by correcting oral hygiene, regulating the diet, and prescribing medicines in the appropriate manner mentioned in the article. In this review, we aimed to review the drugs used in oral mucosal diseases by the dentists who frequently deal with them.

Oral mukoza hastalıklarının tedavisinde kullanılan ilaçlar

Oral mukoza ve çevre dokular çok sayıda sistemik hastalığın belirtilerinin görülebildiği bir bölge olduğu gibi sadece oral mukozaya özgü lezyonların meydana geldiği, vücudun giriş kapısıdır. Ağız mukozasında görülen lezyonların etkeni travma, enfeksiyon, immünolojik ve idiyopatik nedenler olabilir. Oral kaviteyi örten mukoza üzerinde ilaç uygulaması eskiden beri farmakolojinin uğraşı alanı olmuştur. Sistemik hastalıkların belirtisi olarak meydana gelen lezyonlar genelde ülserasyonlar şeklinde görülmektedir. Tedavide hedef, esas olarak altta yatan sebebi çözmekle beraber hasta konforunu arttıran semptomatik tedaviler uygulamaktır. Bunlar başta ağız hijyenini düzeltmek, diyeti düzenlemekle birlikte yazıda belirtilen ilaçların uygun bir şekilde reçete edilmesiyle sağlanır. Bu derlemede oral mukozal hastalıklarla sıklıkla karşılaşan diş hekimlerinin, tedavide uygulamaları gereken ilaçlar hakkında detaylı bilgi verilmesi amaçlanmıştır.

PDF

___

1. Şahin ÖK, Aksoy MÇ. Oral cerrahi işlemler sonrası yara iyileşmesine sigaranın etkileri. Atatürk Üniv Diş Hek Fak Derg 2014; 24: 3.

2. Aksoy H, Özakpınar, ÖB. Yara iyileşmesi ve oksidatif stres. Marmara Pharmaceutical Journal 2014;18:153- 158.

3. Ghosh K, Clark RA. Principles of tissue engineering. Editör: Lanza R, Langer R and Vacanti J. Wound Repair. II. Basic biology of wound repair, Elsevier Academic Press, 2007; 3rd Edition,p.1149-1161.

4. Sen CK, Roy S. Redox signals in wound healing. Biochim Biophys Acta 2008; 1780: 1348-1356.

5. Guo SA, DiPietro, LA. Factors affecting wound healing.L Dent Res 2010; 9: 219-229.

6. Gorski, J, Gannon, F. Current models of steroid hormone action: a critique. Annu Rev Physiol 1976; 38: 425- 450.

7. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017; 39: 2216-2229.

8. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010; 43:7 53-768.

9. Caplan A, Fett N, Rosenbach M, Werth, VP, Micheletti R. G. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017; 76: 1-9.

10. Savage NW, McCullough, MJ.Topical corticosteroids in dental practice. Aust Dent J 2005;50: S40-S44.

11.Piñas L, García-García A, Pérez-Sayáns M, Suárez-Fernández R, Alkhraisat MH, Anitua E. The use of topical corticosteroides in the treatment of oral lichen planus in Spain: A national survey. Med Oral Patol Oral Cir Bucal 2017; 22: e264-e269.

12. Gonzalez‐Moles MA, Bravo M, Gonzalez‐Ruiz L, Ramos P, Gil‐Montoya JA. Outcomes of oral lichen planus and oral lichenoid lesions treated with topical corticosteroid. Oral Diseases 2018; 24: 573-579.

13. Lozada-Nur, F., Miranda, C., & Maliksi, R. Double-blind clinical trial of 0.05% clobetasol proprionate ointment in orabase and 0.05% Fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol and Oral Radiol 1994; 77: 598-604.

14. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992; 21: 456-458.

15. Ceschel GC, Maffei P, Borgia SL, Ronchi C. Design and evaluation of buccal adhesive hydrocortisone acetate (HCA) tablets. Drug Delivery 2001; 8: 161-171.

16. Al-Na'mah ZM, Carson R, Thanoon IAJ. Dexamucobase: A novel treatment for oral aphthous ulceration. Quintessence Int 2009; 40: 399-404.

17. Kiran MS, Vidya S, Aswal GS, Kumar V, Rai V. Systemic and topical steroids in the management of oral mucosal lesions. J Pharm Bioallied Sci 2017; 9(Suppl 1): S1-S3.

18. Guallar IB, Soriano YJ, Lozano AC. Treatment of recurrent aphthous stomatitis. A literature review. J Clin Exp Dent 2014; 6: 168-174.

19. Roopashri G, Jayanthi K, Guruprasad R. Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: A drug trail. Contemp Clin Dent. 2011; 2: 8-12.

20. Skaare AB, Herlofson BB, Barkvoll P. Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol 1996; 23: 778-781.

21. Rösing CK, Cavagni J, Gaio EJ, Muniz FWMG, Ranzan N, Oballe HJR, et al. Efficacy of two mouthwashes with cetylpyridinium chloride: a controlled randomized clinical trial. Braz Oral Res 2017; 31: e47.

22. Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 2006; 14: 558-565.

23. Saxen MA, Ambrosius WT, Rehemtula al-KF, Russell AL, Eckert GJ. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 356-361.

24. Liu J, Zeng X, Chen Q, Cai Y, Chen F, Wang Y, et al. An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter Clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 475-481.

25. Bylka W, Znajdek‐Awiżeń P, Studzińska‐Sroka E, Dańczak‐Pazdrowska A, Brzezińska M. Centella asiatica in dermatology: an overview. Phytother Res 2014; 28:1117-1124.

26. Ajose FO. Some Nigerian plants of dermatologic importance. Int J Dermatol 2007; 46 Suppl 1: 48-55.

27. Mantle D, Gok MA, Lennard TW. Adverse and beneficial effects of plant extracts on skin and skin disorders. Adverse Drug React Toxicol Rev 2001; 20: 89-103.

28. Feily A, Namazi MR. Aloe vera in dermatology: a brief review. G Ital Dermatol Venereol 2009;144:85-91.

29. Surjushe A, Vasani R, Saple DG. Aloe vera: a short review. Indian J Dermatol 2008; 53: 163-166.

30. Sanguigno L, Minale M, Vannini E, Arato G, Riccio R, Casapullo A, et al. Oligosaccharidic fractions derived from Triticum vulgare extract accelerate tissutal repairing processes in in vitro and in vivo models of skin lesions. J Ethnopharmacol 2015; 159: 198-208.

31. Carrasco-Chaumel E, Cardona AF, Ospina EG, Montaño LM, Noemí R, Bleda M, Castro C. Triticum vulgare mouthwashes (TVM) for patients (pts) with oral mucositis (OM) induced by chemotherapy and chemoradiotherapy (ONCOLGroup study). J Clin Oncol 2009; 27(15S): e20570-e20570.

32. Srivastava, JK, Shankar E, Gupta S. Chamomile: a herbal medicine of the past with a bright future. Mol Med Rep 2010; 3: 895-901.

33. Mazokopakis EE, Vrentzos GE, Papadakis JA, Babalis DE, Ganotakis ES. Wild chamomile (Matricaria recutita L.) mouthwashes in methotrexate-induced oral mucositis. Phytomed 2005; 12: 25-27.

34. Mohammadi Nejad S, Özgüneş H, Başaran N. Pharmacological and Toxicological Properties of Eugenol. Turk J Pharm Sci 2017; 14: 201-206.

35. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002; 29: 267-279.

36. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999; 135: 529-532.

37. Yazici H, Pazarli H, Barnes CG. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-285.

38. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G: Double-masked trial of cyclosporine versus colchicine and longterm open study of cyclosporin in Behçet's disease. Lancet 1989; 1: 1093-1096.

39. Beilharz MW, Cummins MJ, Bennett AL, Cummins JM. Oromucosal administration of interferon to humans. Pharmaceuticals (Basel) 2010; 3: 323-344.

40. Picciani BLS, Silva-Junior GO, Barbirato DS, Ramos RT, Cantisano MH. Regression of major recurrent aphthous ulcerations using a combination of intralesional corticosteroids and levamisole: a case report. Clinics 2010; 65: 650-652.

41. Chaidemenos G, Sidiropoulos T, Katsioula P, Koussidou-Eremondi T." Colchicine in the management of mucous membrane pemphigoid. Dermatol Ther 2011; 24: 443-445.

42. Khammissa RAG, Ballyram R, Wood NH, Lemmer J, Feller L. Glucocorticosteroids in the treatment of immune mediated oral diseases. South African Dent J 2016; 71: 62-67.

43. Scully C, Flint SR, Bagan JV, Porter SR, Moos KF. Mucosal, cutaneous and mucocutaneous diseases. In: Scully C, Flint SR, Bagan JV, Porter SR, Moos KF, editors. Oral and Maxillofacial Diseases: Informa Healthcare. 2010. 100-132.

44. Oguz A, Uslukaya O, Alabalık U, Turkoglu A, Kapan M, Bozdag Z. Topical N-acetylcysteine improves wound healing comparable to dexpanthenol: an experimental study. Int Surg 2015; 100: 656-661.

45. Proksch E, de Bony R, Trapp S, Boudon S. Topical use of dexpanthenol: a 70th anniversary article. J Dermatolog Treat 2017; 28: 766-773.

46. Wiederholt T, Heise R, Skazik C, Marquardt Y, Joussen S, Erdmann K, Schröder H, Merk HF, Baron JM. Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol 2009; 18: 969-978.

47. Mandel ID. Antimicrobial mouthrinses: overview and update. J Am Dent Assoc 1994; 125: 2S-10S.

48. Ünür M. Ağız Gargaraları. Diş Hek Derg 2007; 18: 54- 59.

49. Karapinar G, Unur M. Current Approaches in Recurrent Aphthous Stomatitis. Clin Experiment Health Sci 2018; 8: 62-66.